Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Eric Van Cutsem; Rikke Lovendahl Eefsen; Sebastian Ochsenreither; Zanete Zvirbule; Audrius Ivanauskas; Dirk Arnold; Edita Baltruskeviciene; Per Pfeiffer; Jeffrey Yachnin; Rocio Garcia Carbonero; Richard Greil; Christiane Jungels; Laurids Poulsen; Ahmad Awada; Ignacio Garcia Ribas; Nedjad Losic; Joelle Collignon

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Eric Van Cutsem, Rikke Lovendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Dirk Arnold, Edita Baltruskeviciene, Per Pfeiffer, Jeffrey Yachnin, Rocio Garcia Carbonero, Richard Greil, Christiane Jungels, Laurids Poulsen, Ahmad Awada, Ignacio Garcia Ribas, Nedjad Losic, Joelle Collignon

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	40
Issue number	Suppl. 16
Pages (from-to)	4141
ISSN	0732-183X
Publication status	Published - 1 Jun 2022
Event	ASCO Annual Meeting 2022 - Chicago, United States Duration: 3 Jun 2022 → 7 Jun 2022 https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions

Conference

Conference	ASCO Annual Meeting 2022
Country/Territory	United States
City	Chicago
Period	03/06/2022 → 07/06/2022
Internet address	https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions

Access to Document

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4141

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Van Cutsem, E., Eefsen, R. L., Ochsenreither, S., Zvirbule, Z., Ivanauskas, A., Arnold, D., Baltruskeviciene, E., Pfeiffer, P., Yachnin, J., Garcia Carbonero, R., Greil, R., Jungels, C., Poulsen, L., Awada, A., Garcia Ribas, I., Losic, N., & Collignon, J. (2022). Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). Journal of Clinical Oncology, 40(Suppl. 16), 4141. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4141

@article{41e1001543bf46479aaaeb976c04bada,

title = "Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).",

author = "{Van Cutsem}, Eric and Eefsen, {Rikke Lovendahl} and Sebastian Ochsenreither and Zanete Zvirbule and Audrius Ivanauskas and Dirk Arnold and Edita Baltruskeviciene and Per Pfeiffer and Jeffrey Yachnin and {Garcia Carbonero}, Rocio and Richard Greil and Christiane Jungels and Laurids Poulsen and Ahmad Awada and {Garcia Ribas}, Ignacio and Nedjad Losic and Joelle Collignon",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

pages = "4141",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "Suppl. 16",

note = "ASCO Annual Meeting 2022 ; Conference date: 03-06-2022 Through 07-06-2022",

url = "https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions",

}

Van Cutsem, E, Eefsen, RL, Ochsenreither, S, Zvirbule, Z, Ivanauskas, A, Arnold, D, Baltruskeviciene, E, Pfeiffer, P, Yachnin, J, Garcia Carbonero, R, Greil, R, Jungels, C, Poulsen, L, Awada, A, Garcia Ribas, I, Losic, N & Collignon, J 2022, 'Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).', Journal of Clinical Oncology, vol. 40, no. Suppl. 16, pp. 4141. <https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4141>

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). / Van Cutsem, Eric; Eefsen, Rikke Lovendahl; Ochsenreither, Sebastian et al.
In: Journal of Clinical Oncology, Vol. 40, No. Suppl. 16, 01.06.2022, p. 4141.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

AU - Van Cutsem, Eric

AU - Eefsen, Rikke Lovendahl

AU - Ochsenreither, Sebastian

AU - Zvirbule, Zanete

AU - Ivanauskas, Audrius

AU - Arnold, Dirk

AU - Baltruskeviciene, Edita

AU - Pfeiffer, Per

AU - Yachnin, Jeffrey

AU - Garcia Carbonero, Rocio

AU - Greil, Richard

AU - Jungels, Christiane

AU - Poulsen, Laurids

AU - Awada, Ahmad

AU - Garcia Ribas, Ignacio

AU - Losic, Nedjad

AU - Collignon, Joelle

PY - 2022/6/1

Y1 - 2022/6/1

M3 - Conference abstract in journal

SN - 0732-183X

VL - 40

SP - 4141

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - Suppl. 16

T2 - ASCO Annual Meeting 2022

Y2 - 3 June 2022 through 7 June 2022

ER -